ID | 118929 |
Author |
Okuda, Kosaku
Okayama University
Nakahara, Kengo
Okayama University
Ito, Akihiro
RIKEN|Tokyo University
Iijima, Yuta
Okayama University
Nomura, Ryosuke
Okayama University
Kumar, Ashutosh
RIKEN
Fujikawa, Kana
Okayama University
Adachi, Kazuya
Okayama University
Shimada, Yuki
Okayama University
Fujio, Satoshi
Okayama University
Yamamoto, Reina
Okayama University
Takasugi, Nobumasa
Okayama University
Onuma, Kunishige
Tottori University
Osaki, Mitsuhiko
Tottori University
Okada, Futoshi
Tottori University
Ukegawa, Taichi
Okayama University
Takeuchi, Yasuo
Okayama University
Yasui, Norihisa
Okayama University
Yamashita, Atsuko
Okayama University
Marusawa, Hiroyuki
Kyoto University
Matsushita, Yousuke
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Katagiri, Toyomasa
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Shibata, Takahiro
Nagoya University
Uchida, Koji
The University of Tokyo
Niu, Sheng-Yong
Broad Institute of MIT and Harvard
Lang, Nhi B.
The Scripps Research Institute
Nakamura, Tomohiro
The Scripps Research Institute
Zhang, Kam Y. J.
RIKEN
Lipton, Stuart A.
The Scripps Research Institute|University of California, San Diego
Uehara, Takashi
Okayama University
|
Content Type |
Journal Article
|
Description | DNA methyltransferases (DNMTs) catalyze methylation at the C5 position of cytosine with S-adenosyl-L-methionine. Methylation regulates gene expression, serving a variety of physiological and pathophysiological roles. The chemical mechanisms regulating DNMT enzymatic activity, however, are not fully elucidated. Here, we show that protein S-nitrosylation of a cysteine residue in DNMT3B attenuates DNMT3B enzymatic activity and consequent aberrant upregulation of gene expression. These genes include Cyclin D2 (Ccnd2), which is required for neoplastic cell proliferation in some tumor types. In cell-based and in vivo cancer models, only DNMT3B enzymatic activity, and not DNMT1 or DNMT3A, affects Ccnd2 expression. Using structure-based virtual screening, we discovered chemical compounds that specifically inhibit S-nitrosylation without directly affecting DNMT3B enzymatic activity. The lead compound, designated DBIC, inhibits S-nitrosylation of DNMT3B at low concentrations (IC50 ≤ 100 nM). Treatment with DBIC prevents nitric oxide (NO)-induced conversion of human colonic adenoma to adenocarcinoma in vitro. Additionally, in vivo treatment with DBIC strongly attenuates tumor development in a mouse model of carcinogenesis triggered by inflammation-induced generation of NO. Our results demonstrate that de novo DNA methylation mediated by DNMT3B is regulated by NO, and DBIC protects against tumor formation by preventing aberrant S-nitrosylation of DNMT3B.
|
Journal Title |
Nature Communications
|
ISSN | 20411723
|
NCID | AA12645905
|
Publisher | Springer Nature
|
Volume | 14
|
Start Page | 621
|
Published Date | 2023-02-04
|
Rights | This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
|
EDB ID | |
DOI (Published Version) | |
URL ( Publisher's Version ) | |
FullText File | |
language |
eng
|
TextVersion |
Publisher
|
departments |
Institute of Advanced Medical Sciences
|